

Supplementary Information

Different genetic and morphological outcomes for phages targeted by single or multiple CRISPR-Cas spacers

B.N.J. Watson¹, R.A. Easingwood², B. Tong¹, M. Wolf³, G.P.C. Salmond⁴, R.H.J. Staals^{1,5}, M. Bostina^{1,2*} and P.C. Fineran^{1,6*}

Philosophical Transactions of the Royal Society B 2019




Figure S1. Phage-targeting spacers reduce phage infectivity. (a) Schematic of the ϕ M1 genome showing the locations of (b) the RNA polymerase gene (RNP, phiM1_31) with the targeting spacers, and (c) a tail fibre protein gene (TFP, phiM1_44) with the targeting spacers. EOPs and representative plaque morphology images of the (d) anti- ϕ M1 RNP and (e) anti- ϕ M1 TFP strains, with white bars: WT (0 spacers), light grey: 1 \times , mid grey: 2 \times , dark grey: 3 \times and black: 4 \times anti- ϕ spacers. Data shown in the mean +SD ($n=3$). Spacers shared by different strains have been identified with vertical dashed lines (c) and the limit of detection in (d) and (e) is 1×10^{-10} . The plaque image scale bars represent 5 mm. Full details of EOP and plaque size measurements are in table S3.




Figure S2. Phages that replicate on phage-resistant strains are phenotypic or genotypic escapes. (a), (b) & (c) Five plaques were retired on WT (white) and the anti- ϕ strain (grey) from (a) M1 RNP 1, (b) M1 TFP 1 and (c) TE DNP 1. The dashed line represents the EOPs for the strains from figure 1. (d) & (e) 10 plaques were picked and retired on WT (white) and the anti- ϕ strain (grey) from (d) TE TFP 2 and (e) TE TFP 6. The EOPs for the strains were below the limit of detection. (f), (g) & (h) 16 genotypic escape phages, that infected the anti- ϕ strains with an EOP of 1, from (g) TE TFP 2 and (h) TE TFP 6 were screened for deletions using PCR. (f) Schematic showing the ϕ TE TFP gene and the primers used to amplify the region targeted by the (g) TE TFP 2 spacer (PF1635 and PF2146) and the entire gene, plus 200 bp downstream for (h) TE TFP 6 (PF1635 and PF2144, table S2). Product sizes were compared to the Invitrogen 1 kb Plus DNA ladder.




Figure S3. More phages evade CRISPR-Cas targeting of a single spacer through point mutation than deletion or duplication. (a) The consequences of the point mutations on the coding sequence and (b) the frequency type of escape.




Figure S4. Cryo-EM analysis of wild type ϕ TE. (a) Area of a cryo electron micrograph showing ϕ TE phages. (b) Fourier shell correlation (FSC) curve showing a 7.1 Å resolution for the full capsid. (c) Radially coloured surface representation of the capsid showing the T=13 triangulation number. A total of 780 copies of the major capsid protein form 12 pentamers and 120 hexamers that assemble into an icosahedral capsid, which has a maximum diameter of 980 Å. The five-fold axes are indicated by a pentagon, while the centre of the hexamers are indicated by hexagons. At the bottom, the insert shows the segmented densities corresponding to the decoration proteins (blue), hexamers (cyan), and trifolium-like density (red). The decoration protein appears to have a thin, elongated cavity at its interior. (d) Individual density of the major capsid protein (transparent) shows the specific HK97 fold (blue ribbon – protein data bank accession no: 2FT1). (e) Central slice through the map; concentric rings of DNA with a 25 Å spacing are visible inside the capsid (black arrow) and pagoda-shaped decoration proteins (white arrow) are present at the exterior of the capsid and (f) are shown as a slice through the map. (g) Slice through the cryo-EM along the five-fold axis showing the induced curvature on the capsid coat and the interior genome shells.

Table S1. Strains with phage-targeting spacers

Strain	PCF#	#*	Pos†	CRISPR1 sequence‡	Pos	CRISPR2 sequence	Ref
TE DNP							
1	PCF452	1	-1	AACTTATTGAAAAGTCTAAGATCGTATCCGTA			This study
2	PCF461	1	-2	CCTGCTTGCCGTTGAGACTTCCCATGCACTTG			This study
			-1	<i>GAGCGCTTTTCCGCTGCATAACCCCTGCTTCGG</i>			
3	PCF454	1	-1	TCACGCAGTTTAAAGCGCCGCTCTTCGTCAAA			This study
4	PCF455	1	-1	<i>GCGACGATAGTCATGCCCGCGCCACCGGAA</i>	-1	GTCCTCGATTACACGGTCGCAATACTTCCACA	This study
5	PCF456	2	-2	ATGATCAGGCCGTTAAGTTTATTGCTTCAAAA			This study
			-1	TTGTCAGGACGCTGTTTCTTAAACTGGTCCTT			
6	PCF453	2	-2	GTATCCGTAGGCATTGTGACATGCCAAAGCCC	-1	AGATAATTGGCATAATGTTTCTACCCAAAGAAA	This study
			-1	<i>CTTGATCCGGCAAACAACCACCGCTGGTAGC</i>			
7	PCF457	3	-2	TCTCCGGGCAACCACGGGGAAGGGTTCGATCG	-2	CCCAAGTGCATGGGAAGTCTCAACGGCAAGCA	This study
			-1	ATGATCAGGCCGTTAAGTTTATTGCTTCAAAA	-1	<i>TAGGTTGAGGCCGTTGAGCACCGCCCGCAA</i>	
8	PCF460	3			-4	CTGTTTCGCCATGTGTCTTCTACCCTTTCGA	This study
					-3	GATCGTATCGACGTGATGATGAGGGACATCGA	
					-2	<i>TTCTGCATTACGGGCGCTCGGAGGGGAAGTT</i>	
					-1	GATTTCAAAGGACCTCCGGCGAAGTCGTCAA	
9	PCF458	4	-2	GTTTCATCCTTGAACATAAACCTTTTATCGTCT	-2	ATGATCAGGCCGTTAAGTTTATTGCTTCAAAA	This study
			-1	AAAATGAAGCCCGTTGGTCCGCACGGACTGGA	-1	CCCAAGTGCATGGGAAGTCTCAACGGCAAGCA	
TE TFP							
1	PCF194	1	-1	GGCCAGTCCCTTGCGGACCTTCCGGTCCGATT			This study
2	PCF190	1	-1	CTGTGCCGATTTTCAGGGCGTTGGCTGTGTCA			This study
3	PCF189	1	-2	TCAGAACTGGCAACATAAAGACCCTGTCTACT			This study
			-1	<i>TGTTCTTCTTCACTGTCCCTTATTGCGACCT</i>			
4	PCF192	1	-2	TCACATCAACCTGGGTCTTGGCCTTCCAGTT			This study
			-1	<i>AGCTGTCCCTGATGGTCTCATCTACCTGCCT</i>			
5	PCF191	2	-2	TGGGTCCGCTTTGATTTCCAGAGTCTTCTTCG			This study
			-1	CAGATCCTTCTACGAGCACTCTGGCGGGTCT			
6	PCF188	3	-2	AGAAGGGTGACACCGGAGACACCGGTGCAGTG	-1	AAGAATGCCAACGCCGTAAACATCCTCGGTAA	(1)
			-1	GTTTGGCTGGATAACGGTCACTGGTTCCCA			
M1 DNP							
1	PCF247	1	-2	CTCCTTAATGCTCAAGTACTTAACGGAGTTCA			This study
			-1	<i>CCGTACATGAAGTGAAGGGACAGGATGTCCCA</i>			
2	PCF254	1	-1	TACTTGACACAACGACCCACTACAGACGCTAGT			This study
3	PCF253	1	-1	TGCGTAGTGTGTATCAAACCGGTATCTATAAT			This study
4	PCF249	2	-2	ACCGCCGATAGGGTCACGATTACTGTGAGAG	-1	TCGCCAGAGACTTGGGAGACGGGTATCGCAGT	This study
			-1	<i>GGGATGTCCGGGGGTGCTTCACGTAGGCCTT</i>			
5	PCF252	2	-3	<i>CTCAGTTCGGTGTAGGTCGTTGCTCCAAGCT</i>			This study
			-2	ACTTGCGGGTACAGCCGCTCAATCCCTTTGC			
			-1	ATCCAGAGCAGGCACTGTACTGGGGCACGCAC			
6	PCF256	2	-2	ACATTGAATAGTTGCACGGAGTACGTGACTT	-1	ATCCTTGGGCATCTGTCTTCCAAACCACGCA	This study
			-1	ACTTGCGGGTACAGCCGCTCAATCCCTTTGC			
M1 TFP							
1	PCF289	1			-1	AGCCTTAGTTTACTTGCGGGCGATTGGGAACT	This study
2	PCF290	1	-2	ACAACGATATCTCAAACCTAGCTGCCCTGACA			This study
			-1	<i>CTGACGCTCAGTGAACGAAAACCTCAGTTAA</i>			

(Table 3.1 continued)

Strain	PCF#	#*	Pos†	CRISPR1 sequence‡	Pos	CRISPR2 sequence	Ref
3	PCF294	2	-2 -1	GTTTAACCACGCCACTTAGTGCTGCACAGGGT <i>GGTGTGGTCGCCATGATCGCGTAGTCGATAGT</i>	-1	TTCCAGTTCCCAATCGCCCCGAGGTAACCTAA	This study
4	PCF293	2	-1	GTTTAACCACGCCACTTAGTGCTGCACAGGGT	-1	TAGCGCAGTGCTAACCTCGGCGCAGCTATGA	This study
5	PCF292	2	-2 -1	ACAACGATATCTCAAACCTAGCTGCCCTGACA CTAACCCGCTCGCGCGTACGTACCCATTAGC			This study
6	PCF295	3	-3 -2 -1	GTTTAACCACGCCACTTAGTGCTGCACAGGGT <i>AAATCAAAACTGGTGAAACTCAGCCAGGGATT</i> CGGAGCCAGCCCCGTACCCCATTAGTAACT	-2 -1	<i>TCCGCACCAACCGCGAGCCCCGACTCGGTAAT</i> GCACAGCTTAGTGCGGTACAGGCAAACCTACA	This study
7	PCF296	4	-4 -3 -2 -1	GTTTAACCACGCCACTTAGTGCTGCACAGGGT <i>TTAGCGAGGTGCCGCCGGCTTCCATTTCAGGTC</i> TAACCCAGTAATAACCCCTGTACAGGCAGCTA GGTAACACCCCTGTGGTGGTGCACACCAA	-2 -1	<i>ATGTCATGATAATAATGGTTTCTTAGACGTCA</i> CAGATGATTTACCTTGCGCAGGAGTTCAGTGA	This study
TE TMP							
1	PCF258	1			-1	GGATGCCTTCTCCACTCTTTGCCAACCTGAC	This study
2	PCF267	1	-1	TCTTGATGGTGTATGTCACCTTCGACTTTCTGC			This study
3	PCF269	1	-1	TACCCCATAGGCTGCTCCCGCATTTCAGCAGTT			This study
4	PCF273	1	-1	CTGAATGCCTTGTCTGCACCGTCTCGTCCAA			This study
5	PCF266	1	-2 -1	<i>TGACGATGAGCGCATTGTTAGATTTACATACAC</i> TCAGTCTCAAAGTGACTCGGTTCTGTGGTTCT			This study
6	PCF275	1	-1	GCCCAGCAGATGCGCCTGGTGAATAAGCGTTT			This study
7	PCF271	2	-1	CATTGCAACACGGTTACTTTCCAATGCTTTTCG	-1	GCATTCAGGACTTGAACCGCCAGTTCGGTGCT	This study
8	PCF264	2	-2 -1	<i>GTCGATAGTGGCTCCAAGTAGCGAAGCGAGCA</i> <i>CCGATGCCCGCGAAGCGAGAAGAAATCATAAT</i>	-2 -1	GAGGAGCAGAGTTGATCCGGGTAACATTCATC ACGAATTTGATTTCGCTGGCCCGCCTCCTCAGA	This study
9	PCF263	2	-1	AGCAGAGTTGATCCGGGTAACATTCATCGGGC	-2 -1	GCACCTGCACCACGCCAAGACCTGCGCCGTT <i>CGATAGCGGAGTGATACTGGCTTAACATATGC</i>	This study
10	PCF261	2	-1	GAGGAGCAGAGTTGATCCGGGTAACATTCATC	-1	ATACGCTGCTGGGCCATTACATCATCAATGCG	This study
11	PCF268	2	-2 -1	GGAGCCGCATTCATACCAATCGTGCTTTTAC TTTGAGACTGACAAGGCGTCTATGCCCGGGC	-1	<i>TCATGATAATAATGGTTTCTTAGACGTCAGGT</i>	This study
12	PCF274	3	-3 -2 -1	CCAGTCGAATACTTCTTTCAACAGGTCTCCTT TCAGGGACTTGGCAACGATCCTCGACAGTAAT TCGACAAGAAGCTTGACAGTCTTGAAGCGCCA			This study
13	PCF257	3	-3 -2 -1	TTCACCGAAACCACCTTGAAGATTTGGTTCT CATGAAGCCGATTTCTTTCTGGAATGTCTCTT GAATGAAAGGTCAGTTGGCGGAAGGTATCCC			This study
14	PCF259	2	-3 -2 -1	AGCAGGTACAGCAGATGACATCTCCTCGTGCA TTTGAGACTGACAAGGCGTCTATGCCCGGGC ACTACGGATACGGCCTGCCATCGCACGGTTTTT			This study
15	PCF272	3	-1	GTCGCAGCTACGAAGGCCGCTTGGACGAGAC	-2 -1	CCCGGATCAACTCTGCTCCTCTCTCCCTCGT AATACCGACGCGCCGGAGGCGAATACCCATA	This study
16	PCF262	3	-2 -1	GCCTACGACAAATCAGCCAGCAGATGCGCCT TACCCCATAGGCTGCTCCCGCATTTCAGCAGTT	-1	GAGGAGCAGAGTTGATCCGGGTAACATTCATC	This study

*number of phage-targeting spacers †spacer position in array ‡Anti- ϕ spacers with a GG PAM, anti- ϕ spacer with a GA PAM, anti-plasmid spacers with a GG PAM.

Table S2. Plasmids and oligonucleotides used in this study

Name	Description/ sequence (5'-3')	Reference/ description
Plasmids		
pPF712	Priming protospacer, Tc ^R and mCherry	(1)
pPF718	pPF712 with ϕ TE tail fibre protein gene (phiTE_215)	(1)
pPF971	pPF712 with ϕ M1 RNA polymerase gene (phiM1_31)	This study
pPF981	pPF712 with ϕ TE tape measure protein gene (phiTE_228)	This study
pPF1251	pPF712 with ϕ TE DNA polymerase gene (phiTE_10)	This study
pPF1252	pPF712 with ϕ M1 tail fibre protein gene (phiTE_44)	This study
Oligonucleotides		
PF174	CGTTAGAGTGATCGGGCTAC	F for CRISPR1 (binds in leader)
PF175	CAATGGCTCAGGGGATTC	R for CRISPR1 (binds spacer 2)
PF176	GGTAACTACCGTAAAAATAGGAACG	F for CRISPR2 (binds in leader)
PF177	GCCTTTAAGCGCATGTGC	R for CRISPR2 (binds spacer 2)
PF178	CTTTAATAATCTGGTTGTTAGTGTG	F for CRISPR3 (binds in leader)
PF179	CCTCAGAAAGCCGACTTC	R for CRISPR3 (binds spacer 2)
PF1635	TTTGGTACCATAAGGTCGTTGAAGTTCCTGG	F for amplifying ϕ TE TFP (KpnI)
PF1636	TTTCTCGAGCTACAGTAGCAACAGTACCTTTC	R for amplifying ϕ TE TFP (XhoI)
PF1637	TTTGGTACCACAAGAGTTTATATCAGCAACTGG	F for amplifying ϕ M1 RNP (KpnI)
PF1638	TTTCCCGGGATGAAGAATTCAGACTCTCTCACC	R for amplifying ϕ M1 RNP (SmaI)
PF2021	TTTGGTACCACTAATGGCTGCATCTGG	F for amplifying ϕ TE TMP (KpnI)
PF2022	TTTCTCGAGATTGATTAGTTAGGCCACC	R for amplifying ϕ TE TMP (XhoI)
PF2144	CATGAACCATACAATAGCCC	R 200 bp ds of ϕ TE TFP gene
PF2146	TCACGGTTCCAACAAAATGC	R 150 bp ds of ϕ TE TFP 2 spacer
PF2371	TTTCTCGAGATGGATGCACCTTGTAAGTTACC	F for amplifying ϕ TE DNP (XhoI)
PF2372	TTTGGTACCGTATATGATAGCGAGGCCAGC	R for amplifying ϕ TE DNP (KpnI)
PF2373	TTTCTCGAGTACCATTCTGAGTATCCTACC	F for amplifying ϕ M1 TFP (XhoI)
PF2374	TTTCCCGGGAGTCATCAAGCATAACCTCTGC	R for amplifying ϕ M1 TFP (SmaI)

Table S3. Efficiency of plating, plaque sizes and escape type

Strain	No. spacers	EOP \pm sd	Plaque size range (mm)*	Esc type †
WT	0	$1.0 \times 10^0 \pm 2.3 \times 10^{-1}$	2.5-5	
TE DNP				
1	1	$3.6 \times 10^{-1} \pm 3.9 \times 10^{-2}$	0.5-2.5	P/G
2	1	$9.2 \times 10^{-2} \pm 8.7 \times 10^{-3}$	0.5-2.5	P/G
3	1	$9.3 \times 10^{-2} \pm 3.3 \times 10^{-2}$	<0.5-1	P/G
4	1	$1.6 \times 10^{-2} \pm 3.8 \times 10^{-4}$	0.5-1.5	P/G
5	2	$2.2 \times 10^{-2} \pm 4.7 \times 10^{-3}$	<0.5-1.5	P
6	2	$4.0 \times 10^{-3} \pm 9.0 \times 10^{-4}$	<0.5-1	P
7	3	$7.9 \times 10^{-3} \pm 2.0 \times 10^{-3}$	<0.5-1	P
8	3	$1.5 \times 10^{-4} \pm 6.9 \times 10^{-5}$	All <0.5	P
9	4	$3.0 \times 10^{-5} \pm 1.5 \times 10^{-5}$	All <0.5	P
TE TFP				
1	1	$1.9 \times 10^{-1} \pm 3.4 \times 10^{-2}$	0.5-3	P/G
2	1	$9.2 \times 10^{-3} \pm 2.4 \times 10^{-3}$	<0.5-3.5	P/G
3	1	$1.4 \times 10^{-2} \pm 3.0 \times 10^{-3}$	All <0.5	P/G
4	1	$9.1 \times 10^{-3} \pm 1.7 \times 10^{-3}$	0.5-4	P/G
5	2	$2.1 \times 10^{-5} \pm 0.0 \times 10^{-0}$	All <0.5	P
6	3	$1.1 \times 10^{-5} \pm 3.6 \times 10^{-6}$	0.5-3.5	G
WT	0	$1.0 \times 10^0 \pm 2.4 \times 10^{-1}$	2.5-4	
M1 DNP				
1	1	$3.8 \times 10^{-1} \pm 1.3 \times 10^{-1}$	2-4	P
2	1	$6.1 \times 10^{-2} \pm 9.8 \times 10^{-3}$	0.5-2.5	P
3	1	$1.5 \times 10^{-2} \pm 2.7 \times 10^{-3}$	0.5-2	P
4	2	$1.3 \times 10^{-2} \pm 4.8 \times 10^{-3}$	<0.5-2	P
5	2	$1.4 \times 10^{-2} \pm 3.5 \times 10^{-3}$	<0.5-2	P
6	3	$8.3 \times 10^{-4} \pm 1.9 \times 10^{-4}$	<0.5-2	P
M1 TFP				
1	1	$4.0 \times 10^{-1} \pm 1.9 \times 10^{-4}$	2-3	P
2	1	$2.1 \times 10^{-1} \pm 2.7 \times 10^{-2}$	1-2.5	P
3	2	$1.4 \times 10^{-1} \pm 1.2 \times 10^{-1}$	1-2.5	P
4	2	$4.0 \times 10^{-2} \pm 2.6 \times 10^{-2}$	0.5-1.5	P
5	2	$3.1 \times 10^{-2} \pm 2.9 \times 10^{-2}$	0.5-1.5	P
6	3	$2.5 \times 10^{-1} \pm 1.3 \times 10^{-1}$	1-2.5	P
7	3	$8.4 \times 10^{-3} \pm 1.8 \times 10^{-3}$	0.5-1.5	P
WT	0	$1.0 \times 10^0 \pm 2.3 \times 10^{-1}$	2.5-5	
TE TMP				
1	1	$5.1 \times 10^{-2} \pm 1.2 \times 10^{-2}$	0.5-2.5	P/G
2	1	$6.9 \times 10^{-2} \pm 9.2 \times 10^{-3}$	0.5-1.5	P/G
3	1	$7.5 \times 10^{-2} \pm 9.6 \times 10^{-3}$	0.5-1.5	P/G
4	1	$1.5 \times 10^{-2} \pm 5.0 \times 10^{-3}$	0.5-1	P/G
5	1	$3.5 \times 10^{-3} \pm 2.3 \times 10^{-3}$	All <0.5	P/G
6	1	$5.9 \times 10^{-4} \pm 1.4 \times 10^{-4}$	<0.5-3	P/G
7	2	$1.1 \times 10^{-3} \pm 4.8 \times 10^{-4}$	All <0.5	P
8	2	$2.2 \times 10^{-3} \pm 3.4 \times 10^{-4}$	All <0.5	P
9	2	$2.3 \times 10^{-3} \pm 5.0 \times 10^{-4}$	All <0.5	P
10	2	$8.7 \times 10^{-5} \pm 6.2 \times 10^{-5}$	All <0.5	P
11	2	$1.1 \times 10^{-4} \pm 2.7 \times 10^{-5}$	All <0.5	P
12	3	$1.5 \times 10^{-3} \pm 1.2 \times 10^{-4}$	All <0.5	P
13	3	$1.8 \times 10^{-4} \pm 5.2 \times 10^{-5}$	All <0.5	P
14	2	$6.1 \times 10^{-5} \pm 1.7 \times 10^{-5}$	All <0.5	P
15	3	$2.1 \times 10^{-5} \pm 0.0 \times 10^{-0}$	All <0.5	P
16	3	$2.1 \times 10^{-5} \pm 0.0 \times 10^{-0}$	All <0.5	P

*across three replicates; † P=phages that did not heritably escape CRISPR-Cas, G=genotypic escape phages

Table S4. Genotypic escape phages

Esc	Host (TE..)	#*	Mech†	Pos.§	Base change	Codon change	Del/insert size (bp)	Homology/ dup. seq	EOP ±SD
1	TFP 2		del				147	CACG	1.0 ±0.4
2	TFP 2		del				292	AGCCAACG	0.9 ±0.2
3	TFP 2	4	pm	3	A-G	D-G			0.8 ±0.2
4	TFP 2	4	pm	7	A-G				1.0 ±0.2
5	TMP 6	2	del				120	GGCTAAAGCC	0.8 ±0.5
6	TMP 1		pm	2	T-G				1.1 ±0.1
7	TMP 2	2	pm	-1	C-G (CG)	P-R			1.1 ±0.3
8	TMP 1		pm	-1	C-T (AG)	R-C			1.2 ±0.1
9	TMP 1	2	pm	2	T-C				0.8 ±0.1
10	TMP 3		pm	1	A-G	R-S			0.9 ±0.6
11	TMP 6	2	pm	5	C-A	Q-R			0.8 ±0.1
12	TFP 2		pm	5	A-G	T-A			0.9 ±0.2
13	TMP 2		pm	2	C-G	Q-E			0.8 ±0.1
14	TFP 6		del				1,089	TGAAGGGCGA	1.3 ±0.2
15	TFP 6		del				990	GGTGACACCGG	0.8 ±0.6
16	TMP 6		pm	1	T-C	L-S			0.7 ±0.3
17	TMP 4	2	dup‡				15	AGACGTGCAGG ACA	1.0 ±0.2
18	TMP 4	2	dup				15	AGACGTGCAGG ACA	0.9 ±0.1
19	TMP 1	2	pm	25,26, 32	A-T, G-T, C-G	K-I			1.1 ±0.7
20	TFP 3		pm	-2	C-T (GA)	S-F			1.0 ±0.2
21	TMP 3		pm	2	A-G				0.8 ±0.4
22	TMP 4	3	pm	-2	C-A (GT)				1.1 ±0.1
23	TFP 6	3	del				1,968	GACA	1.3 ±0.6
24	TFP 6		del				1,986	GGTCC	1.0 ±0.1
25	TFP 4		pm	-2	C-G (GC)	P-A			0.9 ±0.2
26	TFP 4	2	pm	4	T-C				0.9 ±0.1
27	TFP 4		pm	3	C-T	T-I			0.8 ±0.5
28	TFP 2		del				57	AGCC	1.0 ±0.2
29	TFP 2		pm	-2	C-A (GT)	P-T			1.1 ±0.2
30	TFP 2		del				144	CCTGTG	0.9 ±0.8
31	TFP 2		pm	-1	C-G (CG)	P-R			1.0 ±0.2
32	TFP 3		del				246	GTGTC/ GTATC	1.2 ±0.2
33	TFP 3		pm	1	A-C	S-R			1.1 ±0.2
34	TFP 3		pm	1	A-G	S-G			1.3 ±0.2
35	TFP 1& TFP 6	2	del				1,719	AAGGGTGACAC	0.7 ±0.5 0.8 ±0.2
36	TFP 1		del				462	CCAATCGG/CC GCAGGG	1.4 ±0.4
37	TFP 1		del				729	GGTGACAC	1.2 ±0.3
38	TFP 1		del				783	AAGGGTGACAC TGGCCCAACTG GT	0.7 ±0.4
39	TMP 4		pm‡	-2	C-T (GA)				1.0 ±0.3
40	TMP 4		del‡				45	CCGCC	0.8 ±0.2
41	TMP 5		pm	-1	C-T (AG)				1.0 ±0.0
42	TFP 6		del				2,004	TACTGGTCCAA CAGG	1.1 ±0.0
43	TFP 6		del				1,968	CCGCAGGGTG	1.1 ±0.0
44	TFP 6		del				1,968	AGGTCCAG	1.0 ±0.1

*Number of times isolated; † Mechanism of escape: pm=point mutation, del=deletion, dup=duplication; ‡Esc 5 (120 bp del) background; § position of point mutation: -1, -2=PAM, 1,2,3...=protospacer; || top/coding strand, () new PAM sequence.

Supplementary Reference

1. Pawluk A, Staals RHJ, Taylor C, Watson BNJ, Saha S, Fineran PC, Maxwell KL, Davidson AR. 2016 Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. *Nature Microbiology*; 1(8):16085.